Atea Pharmaceuticals, Inc.

Equities

AVIR

US04683R1068

Biotechnology & Medical Research

Delayed Nasdaq 03:47:11 2024-03-28 pm EDT 5-day change 1st Jan Change
4.025 USD +0.62% Intraday chart for Atea Pharmaceuticals, Inc. -1.83% +31.97%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Atea Pharmaceuticals, Inc. Completes Patient Enrollment in Global Phase 3 Sunrise-3 Trial Evaluating Oral Antiviral Bemnifosbuvir for COVID-19 in High-Risk Patients CI
Atea Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Transcript : Atea Pharmaceuticals, Inc., Q4 2023 Earnings Call, Feb 28, 2024
Atea Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Transcript : Atea Pharmaceuticals, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 10:30 AM
Atea Pharmaceuticals Reports 'Positive' Results on Hepatitis C Virus, COVID Trials; Shares Jump After Hours MT
Atea Pharmaceuticals, Inc. Announces Positive Initial Data from Phase 2 Study for Hepatitis C Virus and Significant Enrollment for Phase 3 SUNRISE-3 Trial for COVID-19 CI
Atea Pharmaceuticals Says Bemnifosbuvir, Ruzasvir Combination Results Show Promise to Treat Hepatitis C Virus MT
Atea Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Transcript : Atea Pharmaceuticals, Inc., Q3 2023 Earnings Call, Nov 08, 2023
Atea Pharmaceuticals, Inc. to Present Bemnifosbuvir and Ruzasvir Data for the Treatment of Hepatitis C Virus at AASLD the Liver Meeting 2023 CI
Transcript : Atea Pharmaceuticals, Inc. Presents at Morgan Stanley 21st Annual Global Healthcare Conference 2023, Sep-13-2023 10:10 AM
North American Morning Briefing : Stock Futures -2- DJ
JPMorgan Downgrades Atea Pharmaceuticals to Underweight From Neutral MT
Atea Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Transcript : Atea Pharmaceuticals, Inc., Q2 2023 Earnings Call, Aug 08, 2023
Atea Pharmaceuticals, Inc.(NasdaqGS:AVIR) dropped from Russell 2000 Value-Defensive Index CI
Atea Pharmaceuticals, Inc.(NasdaqGS:AVIR) dropped from Russell 2000 Defensive Index CI
Atea Pharmaceuticals Doses First Patient in Phase 2 Study of Combination Therapy for Hepatitis C Virus Infection MT
Atea Pharmaceuticals, Inc. Announces First Patient Dosed in Phase 2 Study for Treatment of Hepatitis C with Bemnifosbuvir and Ruzasvir Combination CI
Atea Pharmaceuticals Rejects Acquisition Proposal From Tang Capital Partners Affiliate Concentra Biosciences MT
Concentra Biosciences, LLC cancelled the acquisition of 96.37% stake in Atea Pharmaceuticals, Inc.. CI
Atea Pharmaceuticals Receives Cash Takeover Proposal From Tang Capital Affiliate Concentra Biosciences; Shares Jump MT
Concentra Biosciences, LLC submitted a non-binding proposal to acquire 96.37% stake in Atea Pharmaceuticals, Inc. for approximately $480 million. CI
Atea Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Chart Atea Pharmaceuticals, Inc.
More charts
Atea Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The Company is engaged in is conducting a Phase 3 clinical trial evaluating bemnifosbuvir for the treatment of Coronavirus disease 2019 (COVID-19). It is also conducting a Phase 2 clinical trial evaluating the combination of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV). The bemnifosbuvir (AT-527), is an investigational, novel, orally administered guanosine nucleotide analog polymerase inhibitor that combines a unique nucleotide scaffold with novel double prodrugs for the intended purpose of inhibiting the enzymes central to viral replication. SUNRISE-3 is designed to evaluate bemnifosbuvir as monotherapy, but it is also exploring the effect of combination therapy in a smaller sub-set of patients.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
4
Last Close Price
4 USD
Average target price
4.667 USD
Spread / Average Target
+16.67%
Consensus
  1. Stock
  2. Equities
  3. Stock Atea Pharmaceuticals, Inc. - Nasdaq
  4. News Atea Pharmaceuticals, Inc.
  5. Atea Pharmaceuticals Receives FDA Fast Track for Dengue Treatment